Paxman and Dignitana Merge to Form a Unified MedTech Leader

In a strategic move to expand their presence in the global MedTech market, specifically within the United States, Paxman and Dignitana have announced their merger. This union capitalizes on Paxman's existing market leadership in scalp cooling technologies and aims to advance innovation by combining the strengths of both companies. The acceptance of Paxman's public offer to acquire competitor Dignitana is being hailed as a historical milestone that will enhance their capabilities in managing chemotherapy side effects for cancer patients. The merger will create a unified entity, Paxman AB, committed to elevating the service level by pooling resources and boosting R&D capacities. The consolidation stands to improve insurance reimbursement navigation in the U.S., thereby expanding patient access to important treatment options. As they prepare to launch a new device designed to prevent Chemotherapy-Induced Peripheral Neuropathy (CIPN) by late 2026, the merger provides a significant opportunity to cater to an unmet need and enhance patient quality of life globally.